XVIII Congresso Brasileiro de Obesidade e Síndrome Metabólica
XVIII Congresso Brasileiro de Obesidade e Síndrome Metabólica


Andrew Whittle

Andrew J. Whittle, PhD
Research Scientist, Obesity
Novo Nordisk Research Center Seattle Inc.
Seattle, Washington. USA

Dr. Andrew Whittle is a Research Scientist at Novo Nordisk, based in the Obesity Research Center, Seattle. He received his PhD in Physiology and Metabolism at the University of Cambridge, United Kingdom. Dr. Whittle currently works on the discovery and validation of new targets for the treatment of obesity and its related diseases. His core research interests and expertise lie within the fields of energy balance regulation, and adipose tissue biology. Dr. Whittle has published peer reviewed manuscripts describing factors regulating brown adipose tissue thermogenesis and the central mechanisms that regulate energy expenditure in response to nutritional changes.

Dr. Whittle has been the recipient of an EMBO long-term fellowship to conduct research into the central pathways controlling thermogenesis, and a Stanford Neuroscience Institute Interdisciplinary Research Fellowship. He is currently the Internal Target Diligence Chair at Novo Nordisk Research Center Seattle.

Eric Ravussin

Eric Ravussin, PhD
Boyd Professor
Associate Executive Director Clinical Sciences
Douglas L. Gordon Chair in Diabetes and Metabolism
Director, Nutrition Obesity Research Center,
Pennington Biomedical Research Center-LSU System
Baton Rouge, Louisiana

Dr. Eric Ravussin is a Boyd Professor at Louisiana State University. He received his PhD in human physiology at the University of Lausanne, Switzerland. Dr. Ravussin is an internationally recognized translational investigator in obesity and diabetes research. His research now focuses on the molecular basis of obesity and its co-morbidities. His studies are aimed at understanding the molecular mechanisms that determine the inter-individual variability in energy expenditure, fat oxidation and energy balance in response to caloric restriction, increased or decreased physical activity, overfeeding or physiological conditions such as puberty, pregnancy or menopause. His latest research is in the field of aging with an emphasis on the impact of caloric restriction on human biomarkers of aging and longevity. Dr. Ravussin has published more than 500 peer reviewed manuscripts in the field of obesity, type 2 diabetes and aging. He has mentored more than 60 postdoctoral fellows.

Dr. Ravussin has been the recipient of multiple awards such as: the 1990 Andre Meyer Prize presented by IASO for outstanding achievements in obesity research; the 2001 “E.V. McCollum Award” for actively generating new concepts in nutrition and personally seeing to the execution of studies testing the validity of these concepts (American Society for Clinical Nutrition); the 2010 “Willendorf Award” presented by IASO for outstanding contributions to clinical research in obesity; the 2011 George Bray Founders Award recognizing “significant contributions that advanced the scientific or clinical basis for understanding or treating obesity” presented by TOS; the 2017 Friends of Albert (Mickey) Stunkard Life Achievement Award presented by TOS in remembrance of Dr. Albert (Mickey) Stunkard and recognizes people who have made a lifetime of outstanding contributions to the field of obesity in terms of scholarship, mentorship and education and recently the ASN Class of 2018 Fellows (ASN highest honor). He has been an active member of The Obesity Society, serving on the Council, the program committee and as a former President of the Society from 2006-2008. Dr. Ravussin is Editor in Chief of Obesity since 2012.

Novo Nordisk
Eurofarma Takeda Ache EMS Ottoboni Body Metrix Ethicon
Novo Nordisk
Eurofarma Takeda Ache EMS Ottoboni Body Metrix Ethicon